Status message

Active context: kki_bg_colors_yellow

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dose Study of Nnz-2566 in Fragile X Syndrome

Principal Investigator:

The purpose of this study is to look at the safety of NNZ-2566 for adolescents and adults with Fragile X Syndrome and to determine the drug properties (pharmacokinetic) of NNZ-2566 in people with Fragile X syndrome. The study will also investigate measures of efficacy during treatment.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.